AllSci News
GentiBio secures NIH backing for allogeneic engineered Treg therapy in type 1 diabetes
Cambridge, Massachusetts-based GentiBio, Inc. has received a USD 1.07 million NIH R44 SBIR Phase II grant from the National Institute of Diabetes and...
Taveos' unraveling accelerates as UK joins global regulatory retreat
A rare autoimmune vasculitis treatment has lost its UK authorization after regulators concluded that data underpinning its approval can no longer be...
Boehringer Ingelheim licenses Owkin's K Pro AI platform and immunology data
Boehringer Ingelheim has licensed K Pro, the agentic AI Scientist platform developed by New York and Paris-based Owkin, along with multimodal patient data...
CytoDyn bags another USD 16.5m in PIPE deal to support CCR5-targeted leronlimab
Vancouver, Washington-based CytoDyn Inc. (OTCQB: CYDY) closed a USD 16.5 million private placement to sustain clinical operations and advance its...
Biocytogen grants Qilu non-exclusive license to preclinical VHH antibody for neuroscience
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has granted Qilu Pharmaceutical Co., Ltd. a non-exclusive license to a...
Typewriter emerges with USD 56m to build non-viral in vivo CAR-T platform
Cambridge, Massachusetts-based Typewriter Therapeutics, Inc. has emerged from stealth with a USD 56 million Series A financing round to advance a non-viral,...
Novartis taps Alteogen in USD 3.2b subcutaneous biologics pact
Novartis has entered an option and license agreement with South Korea-based Alteogen Inc. (KOSDAQ: 196170) to develop and commercialize subcutaneous...
Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets
Keymed Biosciences Inc. (HKEX: 02162) has licensed its approved IL-4Rα monoclonal antibody stapokibart (Kangyueda) to Singapore-based Aeira Pte. Ltd. for...
Adicet preps off-the-shelf gamma delta CAR-T for first-in-human prostate cancer study
Redwood City-based Adicet Bio (Nasdaq: ACET) has registered a Phase I/II trial of ADI-212, an allogeneic gamma delta chimeric antigen receptor (CAR) T cell...
Korea's Pharos iBio, Kolon Pharma advance fourth-generation EGFR inhibitor into preclinical
South Korea-based Pharos iBio and Kolon Pharma have signed a joint research and development agreement to co-develop PHI-701, a preclinical EGFR-targeting...
uniQure files AMT-130 BLA after stop-start FDA path
uniQure N.V. (Nasdaq: QURE) has submitted a Biologics License Application (BLA) to the US FDA seeking accelerated approval of ifezuntirgene inilparvovec...
Takeda taps Weave Bio for AI regulatory automation across 14 drug programs
San Francisco-based Weave Bio and Takeda have announced a collaboration to deploy Weave's AI-native regulatory automation platform across 14 of Takeda's...
Norroy advances first domestically developed PSMA-targeted therapy into pivotal China trial
China-based Norroy Bioscience Co., Ltd. has initiated a pivotal Phase III trial of 177Lu-NYM032, a prostate-specific membrane antigen (PSMA)-targeted...
Seoul team extends prime editing to large-scale DNA replacement
Researchers at Seoul National University College of Medicine have developed a prime editing-based system capable of replacing genomic sequences with DNA...
University of Toronto, SickKids develop chemically modified tRNA platform for cystic fibrosis nonsense mutations
A chemically modified, lipid nanoparticle-delivered suppressor transfer RNA platform has restored functional cystic fibrosis transmembrane conductance...
The AllSci Brief
Free, systematic R&D and deal news. Daily.